Guest Speaker - Professor Sarah Tarbrizi, UCL Inst Neurology : “Meeting the Therapeutic Challenge in Huntington's disease”
Huntington’s disease (HD) is a devastating autosomal dominantly inherited neurodegenerative disease for which there is currently no effective disease modifying therapy. The genetic predictability of HD provides an opportunity for early therapeutic intervention many years before overt symptom onset and at a time when reversal or prevention of neural dysfunction may still be possible. As HD is monogenetic, fully penetrant, and characterised by a long premanifest phase, it is emerging as a potential model for studying therapeutic intervention in other neurodegenerative conditions such as Alzheimer’s or Parkinson’s disease where no preclinical diagnostic tests exist. Understanding of HD pathogenesis is evolving, and there are a number of candidate therapeutics with potential disease-modifying effects that are currently being tested. In my talk, I will update on insights into HD pathogenesis, new data to understand the neurobiology of the preclinical phase of neurodegeneration and neural compensation and plasticity in HD, and give an overview on exciting advances working towards HD gene silencing in humans.
Date: 3 February 2017, 13:00 (Friday, 3rd week, Hilary 2017)
Venue: Sherrington Building, off Parks Road OX1 3PT
Venue Details: DPAG, Large Lecture Theatre, Sherrington Building, off South Parks and Parks Road, Oxford OX1 3PT - 01865 272500
Speaker: Professor Sarah Tarbrizi (Dept. of Neurodegenerative Disease, UCL Inst. Of Neurology )
Organising department: Department of Physiology, Anatomy and Genetics (DPAG)
Organiser: Sarah Noujaim (University of Oxford, Department of Physiology Anatomy and Genetics)
Organiser contact email address: matthew.wood@dpag.ox.ac.uk
Host: Professor Matthew Wood (DPAG University of Oxford)
Part of: DPAG Head of Department Seminar Series
Booking required?: Not required
Audience: Members of the University only
Editor: Sarah Noujaim